Navigation Links
Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)
Date:5/20/2013

expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include, among other things, general industry and medical device market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new medical device products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations.

NeuroSigma Contacts:
Dr. Leon Ekchian , President & CEO
Tel: +1-310-479-3100
Email: info@neurosigma.com
NeuroSigma, Inc.
Website: http://www.neurosigma.com

Mr. Mark Collinson , Partner
Tel: +1-310-954-1343
Email: mark.collinson@ccgir.com
CCG Investor Relations
Website: http://www.ccgir.com


'/>"/>
SOURCE NeuroSigma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Positive Clinical Study Results for BSPs HyperQ Technology
3. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
5. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
6. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
7. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
8. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
9. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
10. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
11. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... 2014 Research and Markets has ... Stem Cell Industry Report, 2014-2017" report to their ... cells that can differentiate into specialized cells and can ... cell therapy can be applied to treatment of cardiovascular ... system diseases, damage or lesion of liver, kidney and ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... in the Biotech Industry conference on Friday, September 26, ... Hotel & Conference Center in New York ... at www.meipharma.com . A replay will be available approximately ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... Product Revenue Increased 78 Percent Compared with 2007 - ... - Net Loss Narrows - - Quantitative ... - Conference Call Today ... (Nasdaq: GHDX ) today reported financial results and business progress,for the quarter ended ...
... APS Healthcare, one of the,country,s leading specialty healthcare companies, ... White Plains. The company now,occupies 44,082 square feet of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081105/NY44126LOGO ), Ultimately, the move ... Plains.,To date, the company has hired more than 70 ...
... Nov. 5 As biopharmaceutical,companies continue to ... placed on strategy and execution from development ... revenue growth and little else. In,a continuing ... recent study,was conducted by Best Practices, LLC ...
Cached Biology Technology:Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress 8APS Healthcare Moves Headquarters to White Plains, NY 2New Study Provides Key Findings for Biopharma Product Launch Evaluation 2
(Date:9/18/2014)... celebrated tonight at the third annual Golden Goose Award ... premature infants and in paving the way for the ... supported by the National Science Foundation, the National Institutes ... be honored at a ceremony at the Library of ... of Congress will be on hand to help present ...
(Date:9/18/2014)... Sydney, September 18, 2014 Elsevier, a world-leading ... and services, and the Australasian Research Management Society ... young scientists at the 5th Scopus Young Researcher ... held earlier today at the National Convention Centre ... conference, was attended by guests representing Australia,s and ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2
... A new research study at the University of Delaware ... microorganism that lives in seawater and is related to ... and virulence. V. parahaemolyticus is a ... with the consumption of raw or undercooked seafood, particularly ...
... dogs in western and central Africa comes from a ... ago, probably by European colonialists. In the current issue ... of scientists from Africa, USA and France report that ... country level and that there is only limited movement ...
... beneficial effect of anakinra for rheumatoid arthritis patients, but ... use with other biologic medications. Rheumatoid arthritis is ... in 100 people worldwide. It affects the joints, making ... new breed of arthritis drugs licensed in the past ...
Cached Biology News:UD research study to shed light on emerging seaborne pathogen 2UD research study to shed light on emerging seaborne pathogen 3Hope for a rabies eradication strategy in Africa 2Anakinra for rheumatoid arthritis: A modest benefit with some risk 2
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: